- According to UBS analyst Matthew Roden, total prescriptions for Gilead Sciences' (GILD +0.3%) Harvoni for the week ending November 21 was 4,366 (+21%). Scripts for Harvoni and Sovaldi were 7,813 (+5%). Bloomberg consensus view for Q4 Harvoni sales is $1.8B.
- RBC's Michael Yee cites a Q4 consensus for Harvoni + Sovaldi of ~$3.6B and, if current momentum continues, a 2015 consensus of ~$12B.
Harvoni prescriptions totaled ~4,400 last week
Recommended For You
About GILD Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| GILD | - | - |
| Gilead Sciences, Inc. | ||